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ABSTRACT
Dapsone is chemically sulfonamide with its leprostatic mechanism used in the treatment of Hansen’s disease. It is one of the safest drugs in 
leprosy patients. Apart from its safety, it is associated with various adverse effects such as hemolytic anemia, allergic dermatitis, agranulocytosis, 
methaemoglobinemia, and dapsone hypersensitivity syndrome (DHS). DHS typically presents with fever, skin eruptions, Jaundice, and hepatomegaly 
(organ involvement). We present a case of 35-year-old female attended to Government General Hospital with complaints of fever, skin rashes, and 
yellowish discoloration of the eyes. She had past medication history of dapsone taken for paucibacillary leprosy for 4 weeks. Her symptoms appeared 
after a month and become intolerable to dapsone. Laboratory investigations revealed hepatomegaly, anemic with jaundice. Based on dermatological 
examination, her diagnosis was confirmed as DHS. The drug was stopped and the patient was treated with drugs for the symptomatic cure. She was 
recovered from her condition and the multibacillary leprosy multidrug treatment regimen was continued without dapsone.
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INTRODUCTION
Dapsone (4,4- diamino- diphenyl sulphone) is used in the treatment 
of hypersensitivity disorders, variety of infections. It is most widely 
used as an anti-leprosy drug in the treatment of Hansen’s disease [1]. 
Common side effects associated with the dapsone include hemolytic 
anemia, methemoglobinemia, nausea, and Jaundice, whereas severe life-
threatening adverse effects include dapsone hypersensitivity syndrome 
(DHS) or sulfone syndrome and Toxic Epidermal Necrolysis. DHS is a 
hypersensitivity reaction that occurs due to Dapsone intolerance and was 
first reported in 1950 by Lowe and named by Allday and Barnes [2]. It was 
associated with fever, skin eruptions, and hemolytic anemia that progress 
to jaundice with systemic organ involvement like the liver. The present 
case report emphasizes the 35-year-old female with DHS who was on the 
multibacillary leprosy multidrug treatment (MB-MDT) regimen.
CASE REPORT
A 35-year-old female patient who was on an adult MB-MDT regimen 
for 4 weeks presented to Government General Hospital, Kadapa with 
complaints of yellowish discoloration of the eyes, generalized swelling all 
over the body with loss of appetite. Her medical history signifies that she 
is a known case of Hansen’s disease and has used dapsone 100 mg daily as 
a part of the treatment regimen for 4 weeks. During her admission after 
clear examination, it was found that lesions are multiple popular lesions 
on the face with icterus in the eyes. Her laboratory investigations were 
normal except for Hb – 6 g%, direct bilirubin – 0.7 mg/dl, total protein 
– 5.5 mg/dl, and blood urea – 41 mg/dl. The condition was diagnosed as 
dapsone syndrome with Jaundice and the offending drug was dapsone.
OUTCOME AND FOLLOW-UP
After suspecting the condition, the patient was advised to stop dapsone and 
started treatment to DHS. She was prescribed with ceftriaxone injection 
1 g OD, IV fluids, injection pantoprazole 40 mg OD, tablet doxycycline 
100 mg OD, acetaminophen tablet 500 mg TID, and glycerine lotion, 
ursodeoxycholic acid 300 mg BD. After 8 days of treatment, the patient 
showed significant improvement in her condition and got discharged 
with medications T. Amoxicillin 500 mg BD, T. Ursodeoxycholic acid 300 
mg BD, T. Ondansetron 8 mg BD, and T. Acetaminophen 500 mg BD.
DISCUSSION
Dapsone was used in the treatment of leprosy since 1947 and 
considered as safest drug in anti-leprosy drug regimen, but whereas the 
first report of hypersensitivity to dapsone was first published in 1949 
[3]. The anti-inflammatory effects of dapsone were mainly due to the 
inhibition of neutrophil recruitment as well as the formation of oxidants 
which not only kill the bacteria but also damages the tissues. It starts 
with a triad of symptoms such as fever, skin eruption, and internal organ 
involvement [4]. This was very similar to our presentation, where the 
patient also had a triad of signs. The other possible mechanisms which 
cause DHS were altered hepatic metabolism including the acetylation 
and hydroxylation with toxic metabolite N- Hydroxylamine production 
through N-Hydroxylation pathway is thought to be responsible for 
Dapsone syndrome with hemolytic anemia [5]. Here, the patient also had 
deceased hemoglobin levels which are due to the hemolysis of red blood 
cells. Evidence suggests that hepatic involvement is observed more 
in form of hepatomegaly, cholangitis, and liver failure. HLA-B* 13:01 
single nucleotide polymorphism is a possible predictor of DHS among 
leprosy patients [6]. As the patient is presented with hepatomegaly 
and increased direct bilirubin levels (Fig. 1. Eyes of patient revealing 
yellowish color) which were the possible predictors for the occurrence 
of Jaundice, as it was one of the classical signs of DHS syndrome. In 
contrast to the safety of Dapsone in the MB-MDT regimen apart from 
DHS, it was highly associated with other severe fatal adverse effects 
such as agranulocytosis, toxic epidermal necrolysis, and bone marrow 
suppression particularly in leprosy patients [7]. Our patient responded 
well with the symptomatic treatment and got discharged after 8 days.
CONCLUSION
This case reported the rare and fatal adverse event of dapsone therapy 
and a careful vision is needed on the patients who are on the dapsone 
treatment. This work also signifies the managing of adverse drug 
reactions in MB-MDT for the successful establishment of an anti-
leprosy regimen. Early withdrawal of the causative agent is essential 
to prevent the progression of the reaction. Hence, awareness should 
be created among the people using the MB-MDT regarding their use 
and side effects of drugs which would also be helpful as a part of the 
pharmacovigilance program.
Case Report
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Fig. 1: Eyes of patient revealing yellowish color
